Mitchell Khan (Editor)

Series: Stem Cells – Laboratory and Clinical Research

BISAC: SCI008000

In Chapter 1, the COVID-19 pandemic and the damage mechanisms on the cellular level which can be ameliorated with the cellular therapies is thoroughly evaluated. Previous and ongoing stem cell clinical trial data from diseases with similar symptoms is gathered. All this accumulated data and current clinical trial results indicate that the cellular therapies could be the most effective treatment option for COVID-19 patients to ameliorate the damaged tissues and save lives. In Chapter 2, the authors examine activated mesenchymal stem cells for stroke repair. Stem Cell treatment has shown recovery in animal models of stroke, indicating an improved regenerative and repair potential. Though stem cells are still being used in clinical trials, there is no evidence that they enhance recovery in ischemic stroke patients. Nevertheless, the multipotent mesenchymal stem has widely been explored for stroke recovery. An‘Activated MSC’ as a therapeutic alternative to tackling ischemic stroke is proposed, thereby the activation of MSCs by cytokines, growth factors, hypoxia, pharmacological drugs, etc., could be a novel approach to improving stroke patients’ responses to receiving MSCs. In Chapter 3, the potential benefits of in vitro culture of therapeutic stem cells in the presence of HB along with the ketogenic diet, whereby higher physiological concentrations of ketone bodies can be achieved in vivo, as an adjuvant to stem cell transplantation is assessed.